Weekly weight loss pill shows promise in Mid-Stage trial
NCT ID NCT07281937
First seen Jan 09, 2026 · Last updated May 12, 2026 · Updated 19 times
Summary
This study tests a new weekly pill, VRB-101, to help people with obesity or overweight who also have weight-related health problems lose weight. About 206 adults will receive either the drug or a placebo for several weeks. The main goal is to see how much weight they lose compared to those on placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Study Site 101
Rochester, New York, 14609, United States
-
Clinical Study Site 102
San Antonio, Texas, 78229, United States
-
Clinical Study Site 103
Anniston, Alabama, 36207, United States
-
Clinical Study Site 104
San Antonio, Texas, 78240, United States
-
Clinical Study Site 105
Norman, Oklahoma, 73069, United States
-
Clinical Study Site 106
Wichita, Kansas, 67207, United States
-
Clinical Study Site 107
Montclair, California, 91763, United States
-
Clinical Study Site 108
Monroe, North Carolina, 28112, United States
-
Clinical Study Site 109
Cullman, Alabama, 35055, United States
-
Clinical Study Site 110
Phoenix, Arizona, 85028, United States
-
Clinical Study Site 111
Anaheim, California, 92801, United States
-
Clinical Study Site 112
Dallas, Texas, 75251, United States
-
Clinical Study Site 113
Little Rock, Arkansas, 72205, United States
-
Clinical Study Site 114
Duncansville, Pennsylvania, 16635, United States
-
Clinical Study Site 115
Knoxville, Tennessee, 37909, United States
-
Clinical Study Site 116
West Des Moines, Iowa, 50266, United States
-
Clinical Study Site 117
Binghamton, New York, 13905, United States
-
Clinical Study Site 118
Tarzana, California, 91356, United States
-
Clinical Study Site 119
Decatur, Georgia, 30030, United States
-
Clinical Study Site 120
Charlotte, North Carolina, 28210, United States
-
Clinical Study Site 121
Omaha, Nebraska, 68134, United States
-
Clinical Study Site 122
Southfield, Michigan, 48076, United States
Conditions
Explore the condition pages connected to this study.